{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=7",
    "query": {
      "intervention": "Placebo for Subcutaneous Injection",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 1163,
    "total_pages": 117,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:28:39.152Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05099510",
      "title": "Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Natrunix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "XBiotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-19",
      "completion_date": "2022-08-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099510"
    },
    {
      "nct_id": "NCT03098797",
      "title": "A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Barth Syndrome"
      ],
      "interventions": [
        {
          "name": "Elamipretide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2017-07-05",
      "completion_date": "2021-10-11",
      "has_results": true,
      "last_update_posted_date": "2024-04-16",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03098797"
    },
    {
      "nct_id": "NCT04646603",
      "title": "MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "ARDS, Human",
        "Stem Cells",
        "Regeneration"
      ],
      "interventions": [
        {
          "name": "MRG-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedRegen LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-12-01",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04646603"
    },
    {
      "nct_id": "NCT02346240",
      "title": "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 559,
      "start_date": "2015-02-11",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 19,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02346240"
    },
    {
      "nct_id": "NCT00771810",
      "title": "Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombocytopenia",
        "Neutropenia",
        "Lymphopenia",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "TXA127",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarix Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2008-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 6,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Orange, California + 3 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00771810"
    },
    {
      "nct_id": "NCT07778836",
      "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Friedreich Ataxia",
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "Nomlabofusp",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Larimar Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 150,
      "start_date": "2026-08-05",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Eatontown, New Jersey + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07778836"
    },
    {
      "nct_id": "NCT02319759",
      "title": "Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2015-03-27",
      "completion_date": "2017-01-17",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 12,
      "location_summary": "Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02319759"
    },
    {
      "nct_id": "NCT00552058",
      "title": "Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "certolizumab pegol (CDP870, CZP)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 439,
      "start_date": "2008-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 24,
      "location_summary": "Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00552058"
    },
    {
      "nct_id": "NCT01199289",
      "title": "A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "AMG 827",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 315,
      "start_date": "2010-10-04",
      "completion_date": "2011-12-21",
      "has_results": true,
      "last_update_posted_date": "2021-11-26",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 22,
      "location_summary": "Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01199289"
    },
    {
      "nct_id": "NCT07842640",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Weight Management"
      ],
      "interventions": [
        {
          "name": "ASC35 Injection B, for subcutaneous use",
          "type": "DRUG"
        },
        {
          "name": "ASC35 Placebo Injection B, for subcutaneous use",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascletis Pharma (China) Co., Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2026-08-27",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-18T23:28:39.152Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07842640"
    }
  ]
}